Mechanisms of antineoplastic action of somatostatin analogs

Proceedings of the Society for Experimental Biology and Medicine

Volumn 217, Issue 2, 1998, Pages 143-152

  Pollak, Michael N ^a,c   Schally, Andrew V ^b  

^a MCGILL UNIVERSITY   (Canada)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIS(2 OXOPROPYL)NITROSAMINE; FLUOROURACIL; OCTREOTIDE; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR SUBTYPE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN; VAPREOTIDE;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER HORMONE THERAPY; CELL PROLIFERATION; DRUG RECEPTOR BINDING; ENZYME INDUCTION; GROWTH HORMONE RELEASE; HUMAN; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; SHORT SURVEY;

EID: 0031941299     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-217-44216     Document Type: Short Survey

References (107)

1. Schipper H, Goh CR, Wang TL. Shifting the cancer paradigm: Must we kill to cure? J Clin Oncol 13:801-807, 1995.
2. Schipper H, Turley E, Baum M. A new biological framework for cancer research. Lancet 348:1149-1151, 1996.
3. Schally AV, Comaru-Schally AM. Hypothalamic and other peptine hormones. In: Holland JF, Frei EI, Bast RCJ, Kufe DE, Morton DL, Weichselbaum RR, Ed. Cancer Medicine, 4th ed. Baltimore: Williams and Wilkins, pp1067-1085, 1997.
4. Weckbecker G, Raulf Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 60:245-264, 1993.
5. Schally AV. Oncological applications of somatostatin analogs. Cancer Res 48:6877-6885, 1988.
6. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analog octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 54:6334-6337, 1994.
7. Pollak M, Ingle J, Suman V, Kugler J. Rationale for combined anti-estrogen-somatostatin analog therapy of breast cancer. In: Salmon SE, Eds. Adjuvant Therapy of Cancer VIII: Proceedings of the Eighth International Conference on the Adjuvant Therapy of Cancer, pp 145-152. Philadelphia: J.B. Lippincott, 1997.
8. Sharma K, Patel YC, Srikant C. Subtype specific induction of wild type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688-1696, 1996.
9. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 85:1-22, 1988.
10. Pollak M. Enhancement of the antineoplastic effects of tamoxifen by somatostatin analogs. Digestion 57:(Suppl 1)29-33, 1996.
11. Serri O, Brazeau P, Kachra Z, Posner B. Octreotide inhibits insulin-like growth factor-1 hepatic gene expression in the hypophysectomized rat: Evidence for a direct and indirect mechanism of action. Endocrinology 130:1816-1821, 1992.
12. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogs: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91:2315-2319, 1994.
13. Patel YC, Greenwood MT, Panetta R, Hukovic N, Grigorakis S, Robertson LA, Srikant CB. Molecular biology of somatostatin receptor subtypes. Metabolism 45(Suppl 1):31-38, 1996.
14. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 57:1249-1265, 1995.
15. Schonbrunn A, Gu YZ, Dournard P, Beaudet A, Tannenbaum GS, Brown PJ. Somatostatin receptor subtypes: Specific expression and signalling properties. Metabolism 45(Suppl 1):8-11, 1996.
16. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Rev 16:427-442, 1995.
17. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16:110-115, 1995.
18. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C. Inhibition of cell proliferation by the somatostatin analog RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580-1584, 1995.
19. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 733:138-146, 1994.
20. Lamberts SW, van der Lely A, Deherder WW, Hofland LJ. Drug therapy: Octreotide. New Eng J Med 334:246-254, 1996.
21. Reichlin S. Somatostatin. New Eng J Med 309:1495-1501, 1983.
22. Schally AV, Coy DH, Meyers CA. Hypothalamic regulatory hormones. Annu Rev Biochem 47:89-128, 1978.
23. Berelowitz M, LeRoith D, von Schenk H, Newgard C, Szabo M, Frohman LA, Shiloach J, Roth J. Somatostatin-like immunoactivity and biological activity is present in Tetrahymena pyriformis, a ciliated protozoan. Endocrinol 110:1939-1944, 1982.
24. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. A hypothalamic polypeptide that inhibits the secretion of pituitary growth hormone. Science 179:77-79, 1973.
25. Hobart P, Crawford R, Shen L, Pictet R, Rutter WJ. Cloning and sequence analysis of cDNAs encoding two distinct somatostatin precursors found in the endocrine pancreas of anglerfish. Nature 288:137-141, 1980.
26. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocrine Rev 12:450-482, 1991.
27. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Petcher TJ, Press J. SMS 201-995: A very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci 31:1133-1140, 1982.
28. Veber DF, Freidlinger RM, Perlow DS, Paleveda WJ Jr., Holly FW, Strachan RG, Nutt RF, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, Hirschmann R. A potent cyclic hexapeptide analog of somatostatin. Nature 292:55-58, 1981.
29. Veber DF, Saperstein R, Nutt RF, Freidinger RM, Brady SF, Curley P, Perlow DS, Paleveda WJ, Colton CD, Zacchei AG. A super active cyclic hexapeptide analog of somatostatin. Life Sci 34:1371-1378, 1984.
30. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A 83:1895-1900, 1986.
31. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 16:34-38, 1993.
32. Coy DH, Taylor JE. Receptor-specific somatostatin analogs: Correlations with biological activity. Metabolism 45(Suppl 1):21-23, 1996.
33. Reubi JC. A somatostatin analog inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol 109:108-114, 1985.
34. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 80:2806-2814, 1995.
35. Reubi JC, Schaer JC, Laissue J, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45(Suppl 1):39-41, 1996.
36. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80:2974-2979, 1995.
37. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56:1823-1827, 1996.
38. Maini CL, Sciuto R, Tofani R A, Ferraironi A, Carapella CM, Occhipinti E, Mottolese M, Crecco M. Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nucl Med Commun 16:756-766, 1995.
39. Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3:137-147, 1989.
40. Setyono-Han B, Henkelman MS, Foekens JA, Klijn GM. Direct inhibitory effects of somatostatin (analogs) on the growth of human breast cancer cells. Cancer Res 47:1566-1570, 1987.
41. van Eijck CH, Krenning EP, Bootsma A, Lindemans J, Jeekel J, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343:640-643, 1994.
42. Krenning EP, Kooij PPM, Pauwels O, Breeman WA, Postema PT, De Harder WW, Valkema R, Kwekkeboom DJ. Somatostatin receptor: Scintigraphy and radionuclide therapy. Digestion 57(Suppl 1):57-62, 1996.
43. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993.
44. Palmieri G, Lastoria S, Colao A, Vergara E, Varrella P, Biondi E, Selleri C, Catalano L, Lombardi G, Bianco AR, Salvatore M. Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med 336:263-265, 1997.
45. 1]octreotide. Eur J Nucl Med 21:328-335, 1994.
46. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43:27-35, 1992.
47. Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989.
48. Zhang CY, Yokogoshi Y, Yoshimoto K, Fujinaka Y, Matsumoto K, Saito S. Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 210:805-815, 1995.
49. Srikant CB, Patel YC. Receptor binding of somalostatin-28 is tissue specific. Nature 294:259-260, 1981.
50. Tran VT, Beal MF, Martin JB. Two types of somatostatin receptors differentiated by cyclic somatostatin analogs. Science 228:492-495 1985.
51. Klarlund JK. Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 41:707-717, 1985.
52. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 65:311-320, 1992.
53. Cullen KJ, Yee D, Rosen N. Insulin-like growth factors in human malignancy. Cancer Invest 9:443-454, 1991.
54. Arteaga CL, Kitten U, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK. Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418-1423, 1989.
55. Wajnrajch MP, Gertner JM, Harbison MD, Chua SC, Leibel RL. Nonsense mutation in the human growth hormone releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet 12:88-90, 1996.
56. Jansson JO, Downs TR, Beamer WG, Frohman LA. Receptor-associated resistance to growth hormone-releasing factor in dwarf "little" mice. Science 232:511-512, 1986.
57. Yang XF, Beamer W, Huynh HT, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 56:1509-1511, 1996.
58. Pollak M, Sem A, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84:966-971, 1992.
59. Sekyi-Otu A, Bell R, Andrulis IL, Pollak M. Metastatic behaviour of the RIF-1 murine fibrosarcoma: Inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst 86:628-632, 1994.
60. Pollak M, Polychronakos C, Guyda H. Somatostatin analog SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9:889-892, 1989.
61. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91:12298-12302, 1994.
62. Harding PA, Wang X, Okada S, Chen WY, Wan W, Kopchick JJ. Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem 271:6708-6712, 1996.
63. McGuire WL, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D. Regulation of insulin-like growth factor-binding protein (IG-FBP) expression by breast cancer cells: Use of IGFBP-I as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336-1341, 1992.
64. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogs of IGF-I. Cancer Res 52:6447-6451, 1992.
65. Ambler GR, Butler AA, Padmanabhan J, Breier BH, Gluckman PD. The effects of octreotide on GH receptor and IGF-I expression in the GH-deficient rat. J Endocrinol 149:223-231, 1996.
66. Huynh HT, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analog. Biochem Biophys Res Commun 203:253-259, 1994.
67. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: A potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 75:1459-1463, 1992.
68. Flyvbjerg A, Schuller AG, van Neck JW, Groffen C, Orskov H, Drop SL. Stimulation of hepatic insulin-like growth factor-binding protein-1 and -3 gene expression by octreotide in rats. J Endocrinol 147:545-551, 1995.
69. de Herder WW, Uitterlinden P, van der Lely AJ, Hofland LJ, Lamberts SW. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. Eur J Endocrinol 133:195-199, 1995.
70. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363-1367, 1996.
71. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116:1148-1152, 1994.
72. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Reicher WS. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 55:446-450, 1993.
73. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995.
74. Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 92:141-149, 1992.
75. Baserga R. The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55:249-252, 1995.
76. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463-2469, 1995.
77. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55:303-306, 1995.
78. Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treat 14:307-314, 1989.
79. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21:181-192, 1992.
80. Szende B, Srkalovic G, Schally AV, Lapis K, Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer 65:2279-2290, 1990.
81. Szepeshazi K, Schally AV, Halmos G. Apoptosis in pancreatic cancers of hamsters. Intl J Pancreatology 16:282-287, 1994.
82. Hankinson S, Pollak M, Michaud D, Willet W, Speizer F, the Nurses' Health Study Research Group, Harvard University, Boston. A prospective assessment of plasma insulin-like growth factor levels and breast cancer risk [abstract]. Proc Annual Meeting of the Society of Epidemiological Research, Edmonton, 1997.
83. Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P, Hennekens C, Pollak M. Circulating insulin-like growth factor I and prostate cancer risk: A prospective study. Science, in press, 1998.
84. Juul A, Bang P, Hertel N. Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:1744-752, 1995.
85. Logothetis CJ, Hossan EA, Smith TL. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 14:2731-2734, 1994.
86. Rosenberg L, Barkun AN, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75:23-28, 1995.
87. Poston GH, Schally AV. Somatostatin analogs and pancreatic cancer. Intl J Pancreatology 14:64-66, 1993.
88. Schally AV, Szepeshazi K, Qin Y, Halmos G, Ertl T, Groot K, Cai RZ, Liebow C, Poston GH. Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer. Intl J Pancreatology 16:246-249, 1994.
89. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR in acromegaly: Pharmacokinetic and pharmacodynamic relationships. Metabolism 45(Suppl 1):27-30, 1996.
90. Weckbecker G, Raulf F, Tolcsvai L, Bruns C. Potentiation of the antiproliferative effects of anti-cancer drugs by octreotide in vivo and in vitro. Digestion 57(Suppl 1):4:27-30, 1996.
91. Robbins RJ. Somatostatin and cancer. Metabolism 45(Suppl 1):98-100, 1996.
92. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, SSTR3 mRNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455-3459, 1994.
93. Srikant C, Cai J, Shen S. Inhibition of estrogen stimulated growth of MCF-7 human breast cancer cells by octreotide is potentiated by tamoxifen and involves recruitment of PTP1C to the membrane [abstract]. Proc Annual Meeting Endocrine Society, San Francisco, 1996.
94. Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693-1697, 1990.
95. Pollak M, Ingle JN, Suman VJ, Kugler JW, Nickerson T, Deroo B. Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast cancer patients by coadministration of the somatostatin analog octreotide [abstract]. Proc Annual Meeting American Association for Cancer Research, Washington D.C., 1996.
96. Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res 45:3415-3443, 1985.
97. Bakker GH, Setyono-Han B, Foekens JA, Portengen H, van Putten WL, de Jong FH, Lamberts SW, Reubi JC, Klijn JG. The somatostatin analog sandostatin (SMS 201-995) in treatment of DMBA-induced rat mammary tumors. Breast Cancer Res Treat 17:23-32, 1990.
98. 1]-octreotide scintigraphy. Cancer Res 55(Suppl 23}:5805s-5810s, 1995.
99. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 52:2538-2544, 1992.
100. 6LH-RH and somatostatin analog RC-160 [abstract]. Proc Annual Meeting Endocrine Society, New Orleans, 1993.
101. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: Results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol 13:2012-5, 1995.
102. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 11:148-151, 1993.
103. Szepeshazi K, Lapis K, Schally AV. Effect of combination treatment with analogs of luteinizing hormone releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer 49:260-266, 1991.
104. Radulovic S, Nagy A, Szoke B, Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett 62:263-271, 1992.
105. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93:7269-7273, 1996.
106. Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensly potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 94:652-656, 1997.
107. Nagy A, Armatis P, Schally AV. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 93:2464-2469, 1996.